Citius Pharmaceuticals Files 8-K: Agreements, Equity Sales, Bylaw Changes
Ticker: CTXR · Form: 8-K · Filed: Apr 18, 2025 · CIK: 1506251
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-governance
Related Tickers: CTRS
TL;DR
Citius Pharma inked a deal, sold some stock, and tweaked its bylaws on April 16th.
AI Summary
On April 16, 2025, Citius Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and material modifications to the rights of security holders. Additionally, there were amendments to its articles of incorporation or bylaws and a change in its fiscal year.
Why It Matters
This filing indicates significant corporate actions by Citius Pharmaceuticals, including new agreements and changes to its corporate structure, which could impact its operations and shareholder rights.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- April 16, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-38174 (identifier) — SEC File Number
- 27-3425913 (identifier) — EIN
FAQ
What is the nature of the material definitive agreement entered into by Citius Pharmaceuticals, Inc. on April 16, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by Citius Pharmaceuticals, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided text.
What were the material modifications to the rights of security holders?
The filing notes material modifications to the rights of security holders, but the specifics of these modifications are not elaborated upon in the provided text.
What specific amendments were made to Citius Pharmaceuticals, Inc.'s articles of incorporation or bylaws?
The filing states that there were amendments to the articles of incorporation or bylaws, but the content of these amendments is not specified in the provided text.
What is the new fiscal year end for Citius Pharmaceuticals, Inc.?
The filing indicates a change in the fiscal year, but the new fiscal year end date is not explicitly stated in the provided text, though the previous fiscal year end was 0930.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 18, 2025 regarding Citius Pharmaceuticals, Inc. (CTXR).